|Slideshows|June 29, 2017

Psychiatric Questions, Queries, and Quarrels

Author(s)Cynthia M.A. Geppert, MD, PhD, MA, MPH, MSBE, DPS, MSJ

In psychiatry, hot debates abound if you just look around-and if this Special Report collection is any indication, the result is a balance of opinion and civility made richer by virtue of opposing views.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

ByLenard A. Adler, MD

June 26th 2026

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

ByJessica Walters

June 22nd 2026

Connecting REM Sleep and Substance Use Vulnerability

ByColleen McClung, PhD

June 19th 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Psychiatric Questions, Queries, and Quarrels

Related Content

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Connecting REM Sleep and Substance Use Vulnerability

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

June 2026 in Review: Updates on the Psychiatric Treatment Pipeline